[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100401203":3},{"organization":4,"outcomesModule":7,"designInfo":30,"detailedDescription":37,"studyPopulation":29,"armGroups":38,"interventions":45,"overallOfficials":52,"centralContacts":57,"locations":66,"responsibleParty":117,"collaborators":29,"id":119,"slug":29,"hasResults":120,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":120,"sex":125,"minAge":126,"maxAge":29,"enrollmentInfo":127,"targetDuration":29,"studyType":130,"phases":131,"briefSummary":132,"conditions":133,"keywords":29,"overallStatus":69,"whyStopped":29,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},{"fullName":5,"class":6},"Zoll Medical Corporation","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":29},[9],{"measure":10,"description":11,"timeFrame":12},"Heart Rate Control","The primary objective of this study is to document the percentage achievement in effective HR control (average nighttime HR \\\u003C 70 bpm) during WCD use in female patients.","90 days",[14,17,20,23,26],{"measure":15,"description":16,"timeFrame":12},"Heart Rate Control in Ischemic vs. Non-ischemic Patients","To document the percentage achievement in effective HR control in ischemic vs. non-ischemic patients",{"measure":18,"description":19,"timeFrame":12},"Change in Average Nighttime Resting Heart Rate","Change in Average Nighttime Resting Heart Rate Monitored vs. Historic Heart Rate Control over the course of WCD use.",{"measure":21,"description":22,"timeFrame":12},"Changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ-12)","To observe changes in quality of life over the course of WCD use using the KCCQ-12 Questionnaire. Higher scores on the KCCQ reflect better health status (range 0-100)",{"measure":24,"description":25,"timeFrame":12},"Changes in (European Quality of Life 5 Dimension Questionnaire (EQ-5D-5L)","To observe changes in quality of life over the course of WCD use using the EQ-5D-5L Questionnaire. Higher scores on the EQ-5D-5L reflect better health status (range 0-100)",{"measure":27,"description":28,"timeFrame":12},"Changes in Functional Capacity","To observe changes in functional capacity as measured by average daily step count over the course of WCD use.",null,{"allocation":31,"interventionModel":32,"interventionModelDescription":33,"primaryPurpose":34,"observationalModel":29,"timePerspective":29,"maskingInfo":35},"NA","SINGLE_GROUP","Subjects will wear an FDA-approved WCD with a 3 month follow-up period. Heart rate (HR) will be continuously monitored by the WCD. Every two weeks a report showing daily HR trends will be emailed to the healthcare provider. The healthcare provider will also receive a HR control alert if the HR exceeds a predetermined threshold for 3 days in a row.\n\nBased on this information, clinicians should follow guideline-directed medical therapy (GDMT) to add or titrate medication accordingly. The goal of these changes will be to achieve the average nighttime HR to recommended guidelines (\\\u003C70 bpm) by the end of WCD use.","TREATMENT",{"masking":36,"maskingDescription":29,"whoMasked":29},"NONE","The primary objective of this pilot study is to document the percentage achievement in effective HR control (average nighttime HR \\\u003C 70 bpm) during WCD use in a cohort of female patients with cardiomyopathy in an outpatient setting using continuous heart rate (HR) trends data from the WCD to optimize BB\u002Fivabradine dosage, as compared to a prior historical control.\n\nAdult female patients (18 years or older) who are prescribed the wearable cardioverter defibrillator (WCD) for 3 months for ischemic or non-ischemic cardiomyopathy with a low ejection fraction.\n\nSubjects will wear an FDA-approved WCD with a 3 month follow-up period. Heart rate (HR) will be continuously monitored by the WCD. Every two weeks a report showing daily HR trends will be emailed to the healthcare provider. The healthcare provider will also receive a HR control alert if the HR exceeds a predetermined threshold for 3 days in a row.\n\nBased on this information, clinicians should follow guideline-directed medical therapy (GDMT) to add or titrate medication accordingly. The goal of these changes will be to achieve the average nighttime HR to recommended guidelines (\\\u003C70 bpm) by the end of WCD use.",[39],{"label":40,"type":41,"description":42,"interventionNames":43},"Heart Rate Monitor Enhanced Treatment Optimization","EXPERIMENTAL","Subjects will wear an FDA-approved WCD with a 3 month follow-up period. Heart rate (HR) will be continuously monitored by the WCD.",[44],"Device: Heart Rate Monitor Enhanced Treatment Optimization",[46],{"type":47,"name":40,"description":48,"armGroupLabels":49,"otherNames":50},"DEVICE","Heart rate (HR) will be continuously monitored by the WCD. Every two weeks a report showing daily HR trends will be emailed to the healthcare provider. The healthcare provider will also receive a HR control alert if the HR exceeds a predetermined threshold for 3 days in a row.",[40],[51],"LifeVest Wearable Cardioverter Defibrillator",[53],{"name":54,"affiliation":55,"role":56},"Valentina Kutyifa, MD PHD","University of Rochester","PRINCIPAL_INVESTIGATOR",[58,63],{"name":59,"role":60,"phone":61,"phoneExt":29,"email":62},"Mike Osz","CONTACT","412-968-3333","mosz@zoll.com",{"name":64,"role":60,"phone":61,"phoneExt":29,"email":65},"Tara Roberts","tara.roberts@zoll.com",[67,84,95,107],{"facility":68,"status":69,"city":70,"state":71,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":81},"TriHealth Hatton Research Institute","RECRUITING","Cincinnati","Ohio","45242","United States","US",{"type":76,"coordinates":77},"Point",[78,79],-84.51439,39.12711,{"lat":79,"lon":78},[82],{"name":83,"role":60,"phone":29,"phoneExt":29,"email":29},"Kesari, MD",{"facility":85,"status":86,"city":87,"state":88,"zip":89,"country":73,"countryCode":74,"cosmosGeoPoint":90,"geoPoint":94,"contacts":29},"Texas Cardiology Associates of Houston","TERMINATED","Kingwood","Texas","77339",{"type":76,"coordinates":91},[92,93],-95.18349,30.05691,{"lat":93,"lon":92},{"facility":96,"status":69,"city":97,"state":88,"zip":98,"country":73,"countryCode":74,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"CardioVoyage","McKinney","75020",{"type":76,"coordinates":100},[101,102],-96.61527,33.19762,{"lat":102,"lon":101},[105],{"name":106,"role":60,"phone":29,"phoneExt":29,"email":29},"Abo-Auda, MD",{"facility":108,"status":86,"city":109,"state":110,"zip":111,"country":73,"countryCode":74,"cosmosGeoPoint":112,"geoPoint":116,"contacts":29},"CAMC","Charleston","West Virginia","25304",{"type":76,"coordinates":113},[114,115],-81.63262,38.34982,{"lat":115,"lon":114},{"type":118,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100401203",false,"NCT04504188","Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator","OPT-BB WOMEN","Inclusion Criteria for Screening Phase:\n\n* Female patients with newly diagnosed (never hospitalized for HF in the last 30 days prior to enrollment) ischemic or non-ischemic cardiomyopathy and an EF ≤ 35% at the time of WCD prescription.\n* Patients prescribed the WCD for an intended 90 ± 14 days of use.\n* Patients have used the WCD for no more than 14 days from the day of consent.\n* Patients 18 years of age or older at the time of consent.\n\nInclusion Criteria for Continuation Phase:\n\n-After the first 2 weeks of WCD wear, only actively wearing patients averaging at least 105 hours of WCD wear per week (or 15 hours\u002Fday) are eligible to continue.\n\nExclusion Criteria for Screening Phase:\n\n* Patients with a known contraindication or intolerance to beta-blocker therapy.\n* Patients with permanent atrial fibrillation.\n* Patients who have a pacemaker.\n* Patients with a current or prior implantable cardioverter defibrillator (ICD).\n* Patients who are self-reporting to be pregnant.\n* Patients with known congenital or inherited heart disease.\n* Patients participating in another interventional clinical trial.\n* Patients not expected to live longer than 3 months.\n\nExclusion Criteria for Continuation Phase:\n\n-Patients ending WCD use within the first two weeks of use.","FEMALE","18 Years",{"count":128,"type":129},300,"ESTIMATED","INTERVENTIONAL",[31],"The primary objective of this pilot study is to document the percentage achievement in effective HR control (average nighttime HR \\\u003C 70 bpm) during WCD use in a cohort of female patients with cardiomyopathy in an outpatient setting using continuous heart rate (HR) trends data from the WCD to optimize BB\u002Fivabradine dosage, as compared to a prior historical control.",[134,135],"Cardiomyopathies","Heart Failure","2024-07-23",{"date":138,"type":139},"2024-07-24","ACTUAL",{"date":141,"type":139},"2021-03-08",{"date":143,"type":129},"2024-12",{"name":5,"class":6},4]